WXXWY - WuXi Biologics gains second EMA GMP Certificate for Suzhou Biosafety Testing facility

WuXi Biologics'  (OTCPK:WXXWY) Biosafety Testing facility in Suzhou, China has received its second GMP certificate from the European Medicines Agency (EMA). The Biosafety Testing facility received its first EMA GMP certificate just over a year ago. The team offers cell line characterization and adventitious agent testing for the QC release of cell banks, unprocessed bulk (UPB) lots and raw materials. In April 2021, the facility underwent a remote inspection that covered its entire quality system, including its the Quality Control (QC) testing of a Master Cell Bank (MCB) and Working Cell Bank (WCB) used for the production of an innovative biological product from a global partner.

For further details see:

WuXi Biologics gains second EMA GMP Certificate for Suzhou Biosafety Testing facility